A 52-year-old woman presented with idiopathic active scleritis not responding to oral cyclophosphamide, azathioprine, and oral steroid. Her intraocular pressure in the left eye was 45 mm of Hg in spite of using combination of brinzolamide 1% and brimonidine 0.2% (thrice a day), timolol maleate 0.5% (twice a day) eye drops in both eyes and oral acetazolamide. She was administered subcutaneous golimumab 50 mg injection every 4 weeks along with oral methotrexate 15 mg/week. The scleral inflammation responded and she underwent Ahmed glaucoma valve implantation after two months of initiation of golimumab therapy. After one week of surgery her IOP in left eye was the reduced to 8 mm of Hg. The index case showed that Golimumab can be a useful drug in the management of necrotizing scleritis refractory to the conventional therapy.
The management of glaucoma in patients with scleritis always remains a challenge. The surgical intervention to control the intraocular pressure (IOP) in necrotizing scleritis, the most common subtypes of scleritis associated with secondary glaucoma further adds to the challenge. [1] The higher chances of globe-perforation because of extensive scleral thinning are often the main limiting factor in such cases. Also, reactivation of scleral inflammation following surgery is a major concern for the treating ophthalmologist. Literature on surgical management of glaucoma associated with necrotizing scleritis is sparse. There has been only two reports on Ahmed glaucoma valve (AGV) implantation in patients with necrotizing scleritis available in literature. [2, 3] Golimumab (GLM) is a fully human anti-tumour necrosis factor (TNF)-α monoclonal antibody. Since its first reported use in the treatment of non-infectious uveitis in 2011, [4] various reports on efficacy of the drug in the management of ocular inflammatory diseases have been published. We present a refractory case of necrotizing scleritis with secondary glaucoma, where subcutaneous injection of GLM with oral methotrexate helped to attain resolution of scleral inflammation and IOP control was achieved with an AGV implantation. To the best of our knowledge, the index case is the first report on potential use of GLM in patients with scleritis.
Case Report
A 52-year-old woman presented to our clinic with complaints of recurrent attacks of ocular pain and redness in both eyes for last 6 years. She received a diagnosis of necrotising scleritis, and was extensively investigated. A thorough systemic evaluation for syphilis, tuberculosis, and sarcoidosis was unrevealing. Results of laboratory investigations for vasculitis and rheumatologic disorders were within reference limits. She had undergone phacoemulsification with intraocular lens implantation. She was treated with topical and oral corticosteroid and various immunosuppressives -methotrexate, azathioprine, cyclophosphamide, cyclosporine in these years; but failed to achieve a steroid-free remission. Her best corrected visual acuity was 6/36 in right eye and 6/9 in left eye. Slit-lamp examination of the right eye revealed 360 degree scleral thinning with peripheral corneal thinning and opacity in right eye with a quiet anterior chamber and pseudophakia [ Fig. 1a] . In left eye, diffuse scleral thinning was noted with dilated deeper episcleral vessels, which did not blanch with topical vasoconstrictor [ Fig. 1b-d] . Slit-lamp examination of the left eye also revealed cells 1+, flare 1+ in anterior chamber. IOP measured with Goldman applanation tonometry was 26 mm of Hg in right eye and 45 mm of Hg in left eye. Fundus examination showed clear media with no evidence of posterior segment inflammation. Optic nerve examination revealed increased vertical cup: Disc ratios of 0.8 with bipolar thinning in the right eye and 0.9 with near total cupping in left eye. She was on oral corticosteroid (10 mg every day), oral cyclophosphamide (50 mg twice a day), oral azathioprine (50 mg twice a day). She was also using a combination of brinzolamide 1% and brimonidine 0.2% (thrice a day), timolol maleate 0.5% (twice a day) eye drops in her both eyes and was on oral acetazolamide 250 mg four times a day. A decision to insert Ahmed glaucoma valve was suggested after proper control of scleritis. She was subsequently administered subcutaneous golimumab 50 mg and started on oral methotrexate (15 mg/week) under the care This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. 
Discussion
The cause of glaucoma in scleritis patients can be multi-factorial and can be due to obstruction of the trabecular meshwork by inflammatory cells, peripheral anterior synechiae and/or posterior synechiae related or due to steroid response. [5] The concurrent anterior uveitis, presence of synechia, previous cataract surgery and corneal involvements are the other reported risk factors for increased IOP in patients with scleritis. [1] Over the last few years, drainage implants have become popular and increasingly being advocated for the treatment of uveitic glaucoma with high published success rates. However, the literature on AGV implantation in patients with necrotizing scleritis is sparse. Ranjan and Rao [2] described a case of necrotizing scleritis with extensive staphylomas and secondary glaucoma in a 35-year-old one eyed female. The patient underwent AGV implant and had good control IOP post-operatively. After three and half months, she presented with recurrence of scleral inflammation with scleral melt leading to exposure of the valve for which she required patch graft. [2] Goel et al. [3] described a patient with bilateral idiopathic healed sclerokeratouveitis with ciliary and intercalary staphyloma where phacoemulsification with intraocular lens implantation and AGV implant were performed as a single-stage procedure for complicated cataract and secondary glaucoma in the left eye. A cadaveric scleral graft was used to cover the AGV and the post-operative outcome was good except for severe anterior chamber inflammation on the second day. [3] Necrotising scleritis, though rare, is the most severe form of the scleral inflammation. Immunosuppressive agents are often considered as first-line of therapy in the management of necrotizing scleritis. Though, reported to have a higher association with systemic rheumatic diseases than other subtypes of scleritis, necrotizing scleritis can be idiopathic. [6] Management of necrotizing scleritis, refractory to the conventional immunosuppressive therapy is challenging. In our case, it was further complicated by the secondary glaucoma. Various biological agents has been successfully used in the management of refractory necrotizing scleritis. [7, 8] The scleral inflammation in our patient was resistant to conventional immunosuppressives, but responded to subcutaneous injection of GLM which helped us to perform AGV implantation. GLM, which requires once a month injection, has been found to be effective in the management of recalcitrant cases of uveitis. [9, 10] Our report suggests that GLM can be a useful drug in the management of necrotizing scleritis refractory to the conventional therapy. However, further research is needed to ensure the safety and efficacy of the drug in patients with necrotizing scleritis.
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Posterior scleritis is an uncommon and relatively unrecognized form of scleral inflammation. It has been reported to account for 2%-12% of all cases of scleritis. [1] Posterior scleritis is known for its protean fundus pictures: choroidal folds or retinal striae, optic nerve head edema, circumscribed mass and exudative retinal detachment. [1] Scleral inflammation can be the initial manifestation of an unexpected systemic disease. Posterior scleritis is associated with a systemic disorder in as many as in 30% of patients [1] and rarely has been described as a result of infectious process. However, infection of the sclera following the spread of a local or systemic infectious disease process is not uncommon. [2] [3] [4] [5] It is important to rule out infectious etiology in scleritis as infectious scleritis may be clinically identical to that caused by systemic autoimmune disease. This article, apart from reporting a case, is also a succinct review of posterior scleritis due to tuberculosis, which highlights the challenges in diagnosis and management of such cases.
Case Report
A 47-year-old female presented to our clinic with complaints of diminution of vision in the left eye with ocular pain since 15 days. She consulted an ophthalmologist locally and was on topical steroids for last 10 days. There was a history of contact with a patient of pulmonary tuberculosis. On examination, her best corrected visual acuity (BCVA) was 6/6 in the right eye and 6/18 in the left eye. Slit-lamp examination of the left eye showed a quiet anterior chamber, cells in anterior vitreous. Pupils were normal and reactive in both the eyes and colour vision with Ishihara chart was 21/21 in both eyes. Slit-lamp and fundus examination of the right eye was unremarkable. Fundus examination of the left eye showed an oedematous optic disc with surrounding subretinal fluid and scattered multiple, discrete areas of choroiditis in mid-and far-periphery [ Fig. 1a] . Ultrasound B-scan of the left eye demonstrated sclerochoroidal thickening with widening of sub-Tenon space with scant fluid and elevation of optic papilla [ Fig. 1b] . Fundus fluorescein angiography (FFA) of the left eye showed early disc staining
